ORIGINAL RESEARCH

Pathological Insights into Emerging Infectious Diseases and the Role of Antiviral and Antibiotic Treatments in Mitigating Public Health Risks

Vaibhav Mandava[1], Abhilasha Sharma[2]

[1]Assistant Professor, Department of General Medicine, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India
[2]Assistant Professor, Department of Pathology, Viswabharathi Medical College & General Hospital, Ulchala, Kurnool, Andhra Pradesh, India

Corresponding author
Abhilasha Sharma
Assistant Professor, Department of Pathology, Viswabharathi Medical College & General Hospital, Ulchala, Kurnool, Andhra Pradesh, India
Email: Abhilasha.rntmc@gmail.com

Received: 22 February, 2020 Accepted: 25 March, 2020

ABSTRACT

Background: Emerging infectious diseases (EIDs) represent a growing global health threat, driven by factors such as zoonotic transmission, environmental changes, and globalization. Understanding the pathological mechanisms of EIDs and the role of antiviral and antibiotic treatments is critical for mitigating public health risks.**Objectives**: This study aimed to investigate public knowledge, perceptions, and behavioral practices regarding EIDs and evaluate the perceived effectiveness of antiviral and antibiotic treatments. It also sought to identify barriers to treatment access and adherence.**Methods**: A cross-sectional study was conducted with 220 participants selected through stratified random sampling. Data were collected using a structured questionnaire covering demographics, knowledge, treatment perceptions, and behavioral practices. **Results**: Antiviral treatments were perceived as "highly effective" by 65% of participants, while antibiotics were rated similarly by 85%. However, 40% expressed concerns about drug resistance. Behavioral practices indicated that 30% of participants engaged in self-medication, particularly in rural areas. Challenges in accessing treatments, including affordability and availability, were reported by 40% of participants. Positive perceptions of vaccination were observed in 80% of participants, though 20% reported vaccine hesitancy.**Conclusion**: It is concluded that while awareness of EIDs is high, significant gaps in knowledge and behavioral practices persist, contributing to issues such as antimicrobial resistance and limited treatment adherence. Public health interventions focusing on education, improved healthcare access, and vaccination advocacy are essential.

INTRODUCTION

Emerging infectious diseases (EIDs) have become a growing concern for global health in recent decades. Defined as diseases caused by newly identified pathogens or existing pathogens that have significantly increased in prevalence, EIDs often emerge due to dynamic interactions between humans, animals, and the environment [1]. Globalization, urbanization, deforestation, and climate change have intensified the spread and adaptation of infectious agents, making communities increasingly vulnerable to outbreaks. High-profile diseases such as COVID-19, Ebola, Zika, and SARS have underscored the urgency of understanding EIDs and developing effective strategies to mitigate their impact [2].The pathological mechanisms of EIDs are complex and multifaceted, often involving rapid genetic evolution of pathogens, host immune response disruptions, and environmental factors that facilitate transmission. For example, zoonotic diseases, which are transmitted from animals to humans, have been identified as a significant source of EIDs [3]. Viruses such as coronaviruses, influenza, and hantaviruses have demonstrated the capacity to jump species barriers, adapt to new hosts, and evade immune defenses, leading to widespread infections. These mechanisms not only increase the transmissibility of pathogens but

also complicate diagnosis and treatment, particularly in resource-limited settings [4].

The role of antiviral and antibiotic treatments in combating EIDs cannot be overstated. Antivirals are specifically designed to target viral replication cycles, interrupting processes such as entry, replication, or assembly of the virus within the host. For instance, drugs like remdesivir and monoclonal antibodies have shown promise in treating diseases like COVID-19, while antiretrovirals have been instrumental in managing HIV/AIDS [5]. Despite these advancements, challenges remain, including the emergence of drug-resistant viral strains, limited access to antiviral medications in low-income regions, and the need for early and accurate diagnosis to maximize treatment efficacy [6].Antibiotics, on the other hand, are critical for managing bacterial infections and secondary complications arising from viral diseases. Secondary bacterial infections, such as pneumonia during influenza outbreaks, exacerbate morbidity and mortality rates, emphasizing the importance of antibiotics in comprehensive treatment plans. However, the widespread misuse and overuse of antibiotics have led to an alarming rise in antimicrobial resistance (AMR). Resistant pathogens, often referred to as "superbugs," reduce the effectiveness of existing treatments, making infections harder to treat and increasing the risk of disease spread, severe illness, and death [7].

The intersection of EIDs, antiviral therapies, and antibiotic stewardship presents a unique opportunity to develop innovative solutions to public health challenges. Strengthening global surveillance systems to identify and monitor emerging pathogens is essential for early intervention and containment [8]. Investments in research and development of broad-spectrum antivirals and novel antibiotics are critical to staying ahead of rapidly evolving pathogens. Moreover, public health initiatives to promote rational use of medications, enhance vaccination programs, and improve access to healthcare can significantly reduce the burden of EIDs [9].

Objective

This study aimed to investigate public knowledge, perceptions, and behavioral practices regarding EIDs and evaluate the perceived effectiveness of antiviral and antibiotic treatments. It also sought to identify barriers to treatment access and adherence.

Methodology

This cross-sectional study was conducted and involved 220 participants selected using stratified random sampling to ensure a diverse representation of demographics. Participants included healthcare professionals, individuals with a history of infectious diseases, and residents from communities with a high prevalence of EIDs.

Data Collection

Data were collected exclusively through a structured questionnaire designed to gather both quantitative and qualitative information. The questionnaire was divided into three main sections. The first section focused on demographic information, including age, gender, education level, and residential environment. The second section assessed participants' knowledge and awareness of EIDs, such as their understanding of causes, risk factors, and available treatments. The final section explored participants' personal or family experiences with infectious diseases, perceptions of treatment effectiveness, and concerns about issues like drug resistance. The questionnaire also included open-ended questions to capture in-depth qualitative insights.The questionnaire was distributed using two methods to ensure accessibility for all participants. An online version was shared through email and social media platforms, allowing urban participants and those with internet access to respond conveniently. In rural or underrepresented areas, paper-based questionnaires were distributed with the assistance of local health workers, ensuring inclusivity. Both formats provided participants with clear instructions and access to guidance for clarifications.

Validation and Pilot Testing

To ensure the reliability and validity of the questionnaire, it was subjected to pilot testing with 20 participants prior to full-scale distribution. This process helped identify any ambiguities in the questions and allowed for refinements to the language and structure. Feedback from the pilot group was incorporated, resulting in a user-friendly and effective questionnaire that met the study's objectives.

Data Analysis

Data were analyzed using SPSS v16. Inferential statistical techniques, such as chi-square tests and regression analysis, were applied to identify patterns, correlations, and relationships within the data. Qualitative responses to open-ended questions were thematically analyzed to provide contextual insights, complementing the quantitative results.

RESULTS

The study included a total of 220 participants, with 50% male and 50% female participants, ensuring balanced insights. Most participants (40%) belonged to the 30–45 age group, followed by 18–29 years (35%) and 46+ years (25%). Regarding education, 60% held a university degree, while 25% had completed secondary education, and 15% had primary or no education. Urban residents made up 65% of the sample, compared to 35% from rural areas, reflecting a stronger urban representation in the study.

Table 1: Demographic Information of Participants

Demographics	Number of Participants (N=220)	Percentage (%)
Gender		
Male	110	50
Female	110	50
Age Group		
18–29 years	77	35
30–45 years	88	40
46+ years	55	25
Education Level		
University Degree	132	60
Secondary Education	55	25
Primary/No Education	33	15
Residence		
Urban	143	65
Rural	77	35

A high level of awareness was observed, with 85% of participants reporting knowledge of EIDs and 70% familiar with zoonotic transmission. However, only 45% recognized the role of environmental factors in the spread of EIDs. Awareness of antiviral treatments was noted in 75%, but only half (50%) could name common antiviral drugs.

Table 2: Knowledge and Awareness of Emerging Infectious Diseases (EIDs)

Awareness	Number of Participants	Percentage (%)
Aware of EIDs	187	85
Familiar with zoonotic transmission	154	70
Familiar with environmental risk factors	99	45
Aware of antiviral treatments	165	75
Familiar with common antiviral drugs	110	50
Aware of antibiotics	209	95
Misbelief: Antibiotics effective for viruses	132	60

A significant proportion of participants (65%) reported personal or familial experiences with infectious diseases. Among those, 70% adhered to prescribed treatments, but 30% engaged in self-medication or prematurely stopped treatments. Challenges in accessing treatments were reported by 40%, with affordability being a concern for 25%.

Table 3: Experiences with Infectious Diseases

Experience	Number of Participants	Percentage (%)
Personal or family history of infectious diseases	143	65
Adhered to prescribed treatments	154	70
Stopped treatment/self-medicated	66	30
Challenges in accessing treatments	88	40
Affordability concerns	55	25

Antibiotic treatments were perceived as more effective, with 85% of participants rating them as highly effective, compared to 65% for antiviral treatments. Moderate effectiveness was reported for 25% of antivirals and 10% of antibiotics. Ineffectiveness ratings were low for both treatment types, at 10% for antivirals and 5% for antibiotics, reflecting general satisfaction with their effectiveness but also indicating areas for improvement in antiviral therapies.

Table 4: Perceived Effectiveness of Treatments

Treatment Type	Highly Effective (%)	Moderately Effective (%)	Ineffective (%)
Antiviral Treatments	65	25	10
Antibiotic Treatments	85	10	5

A majority (70%) of participants followed prescribed medication use, but 30% admitted to self-medicating with antibiotics, with rural areas showing a higher prevalence (50%) compared to urban areas (20%). Vaccination was positively perceived by 80% of participants, reflecting its acceptance as a preventive measure. However,

vaccine hesitancy persisted among 20%, driven by safety concerns, emphasizing the need for targeted awareness campaigns to address misinformation.

Table 5: Behavioral Practices and Vaccination

Behavioral Practice	Number of Participants	Percentage (%)
Followed prescribed medication use	154	70
Self-medicated with antibiotics	66	30
Rural self-medication prevalence	38	50
Urban self-medication prevalence	28	20
Positive perception of vaccination	176	80
Vaccine hesitancy	44	20

DISCUSSION

Emerging infectious diseases (EIDs) continue to pose significant challenges to public health, requiring a comprehensive understanding of their pathology and effective strategies for mitigation. The findings of this study highlight key areas of knowledge, perceptions, and behavioral practices among participants, shedding light on the effectiveness of antiviral and antibiotic treatments and the public's response to these therapeutic measures [10].The study revealed high levels of awareness of EIDs among participants (85%), with a substantial proportion familiar with zoonotic transmission and risk factors. However, gaps in understanding were evident, particularly regarding environmental drivers of disease emergence and the role of antibiotics. Nearly 60% of participants mistakenly believed that antibiotics are effective against viral infections [11,12]. This misconception underscores the need for targeted educational campaigns to enhance public understanding of the appropriate use of antibiotics and antivirals.Participants generally rated antiviral and antibiotic treatments as effective, with antibiotics receiving higher ratings of "highly effective" (85%) compared to antivirals (65%) [13]. This difference may reflect the more established use of antibiotics in treating bacterial infections and the relatively recent development of some antiviral therapies. Concerns about drug resistance were notable, with 40% of participants, particularly healthcare professionals, expressing apprehension about the growing threat of antimicrobial resistance (AMR). This highlights the urgent need for policies promoting antibiotic stewardship and the development of novel therapeutics to combat resistant pathogens [14].The study identified significant challenges in treatment adherence and accessibility, particularly among rural participants. Approximately 30% of participants reported self-medicating with antibiotics, a practice more common in rural areas where access to healthcare services is limited. This behavior not only contributes to AMR but also raises concerns about the misuse of medications [15]. Similarly, 40% of participants reported difficulties accessing treatments, with affordability and availability being key barriers. These findings emphasize the importance of improving healthcare infrastructure, particularly in underrepresented areas, to ensure equitable access to essential medicines [16].Vaccination was widely viewed as a preventive measure, with 80% of participants expressing positive perceptions. However, vaccine hesitancy was reported by 20% of participants, citing concerns about safety and side effects. This hesitancy aligns with global trends and highlights the need for transparent communication from public health authorities to build trust and increase vaccine uptake. Strengthening vaccination programs can significantly reduce the burden of EIDs and minimize reliance on therapeutic interventions 7].The results of this study underscore the multifaceted nature of addressing EIDs, involving public education, improved healthcare access, and the promotion of responsible medication use. Policies aimed at enhancing awareness, combating misinformation, and encouraging preventive measures such as vaccination are essential [8]. Additionally, investments in research and development of new antivirals and antibiotics are critical to staying ahead of evolving pathogens.This study relied on self-reported data, which may introduce bias or inaccuracies in responses. While the sample size of 220 participants provided valuable insights, larger and more diverse samples would improve the generalizability of the findings. Future studies could also explore the role of socioeconomic and cultural factors in shaping knowledge and behavior regarding EIDs.

CONCLUSION

It is concluded that emerging infectious diseases (EIDs) pose a significant threat to global health, demanding a multifaceted approach to understanding their pathology and mitigating their impact. This study highlights that while awareness of EIDs is generally high among participants, critical gaps in understanding persist, particularly regarding the misuse of antibiotics and the role of antivirals.

REFERENCES

1. National Institutes of Health (US); Biological Sciences Curriculum Study. NIH Curriculum Supplement Series [Internet]. Bethesda (MD): National Institutes of Health (US); 2007. Understanding Emerging and Re-emerging Infectious Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK20370/

2. Morens DM, Fauci AS. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog. 2013;9:e1003467.
3. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci. 2001;356:983–9.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13
5. Fauci AS. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell. 2006;124:665–70
6. Babkin IV, Babkina IN. The origin of the variola virus. Viruses. 2015;7:1100–12.
7. Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, et al. Plague: past, present, and future. PLoS Med. 2008;5:e3.
8. Racaniello VR. Emerging infectious diseases. J Clin Investig. 2004;113:796–8.
9. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012;20:313–9.
10. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80:62–73.
11. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014. ISBN 978-92-4-156474-8.
12. Steinmann J, Dittmer S, Houbraken J, Buer J, Rath PM. In vitro activity of isavuconazole against Rasamsonia species. Antimicrob Agents Chemother. 2016;60:6890–1.
13. de Lima Barros MB, de Almeida Paes R, Schubach AO. Sporothrix schenckii and sporotrichosis. Clin Microbiol Rev. 2011;24:633–54.
14. Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477–84
15. Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995;1:7–15.
16. Vouga M, Greub G. Emerging bacterial pathogens: the past and beyond. Clin Microbiol Infect. 2016;22:12–21.